First-in-class intranasal epinephrine spray for anaphylaxis: Dose finding clinical study
FMXIN002 4.0 mg nasal spray enables faster and higher epinephrine plasma absorbance at the short therapeutic window required for the treatment of anaphylaxis, using a patient-friendly, needle-free, stable and safe device.
Authors
- Alon Y. Hershko (ORCID: https://orcid.org/0000-0002-7602-483X)
- Tair Lapidot (ORCID: https://orcid.org/0000-0003-3229-1212)
- Simcha Blotnick
- Carolina Abrutzky
- Yuval Tal (ORCID: https://orcid.org/0000-0002-3633-2520)
- Dalia Megiddo (ORCID: https://orcid.org/0000-0003-4305-9048)
- Oded Shamriz (ORCID: https://orcid.org/0000-0003-3188-2707)
- Galia Temtsin Krayz
- Yoseph Caraco (ORCID: https://orcid.org/0000-0002-7959-2517)
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Mapi Pharma (Israel) (IL)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1016/j.jacig.2025.100487
- Citations
- 1
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.62